CytomX - Model BMS-986249 -CTLA-4 - Directed Probody Therapeutic

Bristol Myers Squibb initiated a Phase 2 randomized 5-arm cohort expansion study in its ongoing first-in-human Phase 1/2a trial of the anti-CTLA-4 Probody BMS-986249, a Probody version of the anti-CTLA-4 antibody Yervoy® (ipilimumab), in combination with Opdivo® (nivolumab) in patients with metastatic melanoma (NCT03369223).